Intervention Protocol

Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis

  1. Ian P Sinha1,
  2. Kevin W Southern1,
  3. Kerry Dwan2,
  4. Sanjay Patel1,*

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 24 FEB 2014

Assessed as up-to-date: 6 FEB 2014

DOI: 10.1002/14651858.CD010966


How to Cite

Sinha IP, Southern KW, Dwan K, Patel S. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD010966. DOI: 10.1002/14651858.CD010966.

Author Information

  1. 1

    University of Liverpool, Department of Women's and Children's Health, Liverpool, Merseyside, UK

  2. 2

    University of Liverpool, Department of Biostatistics, Liverpool, England, UK

*Sanjay Patel, Department of Women's and Children's Health, University of Liverpool, Alder Hey Children's Foundation Trust, Eaton Road, Liverpool, Merseyside, L12 2AP, UK. sanjay19patel@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 24 FEB 2014

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the effects of CFTR correctors on clinically important outcomes in children and adults with CF. The clinically important outcomes will include both benefits and harms that participants may experience.